Navigation Links
Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
Date:12/3/2007

Results Show Statistically Significant Indications of PS433540's Potential

in Treating Hypertension

PRINCETON, N.J., Dec. 3 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced today additional results from the Company's Phase 1 multiple ascending dose (MAD) study of its lead internal product candidate, PS433540 (DARA). Data demonstrated that PS433540 produced statistically significant, dose dependent increases in plasma-renin activity levels, as well as reductions in systolic and diastolic blood pressure. These findings are in addition to previously reported initial results from the MAD trial that showed all doses of PS433540 to be safe and well-tolerated. This MAD study was designed to evaluate the 14-day safety and tolerability of 50, 100, 250, 500 and 1,000 mg doses of PS433540 in healthy volunteers.

The trial's positive plasma-renin activity and blood pressure findings provide preliminary insight into the potential of PS433540 to treat hypertension. Study investigators witnessed a dose dependent increase in plasma-renin activity levels for PS433540, which was more pronounced at Day 15 than at Day 1. This observed increase in plasma-renin activity is indicative of PS433540's ability to block the angiotensin receptor, a key target in efforts to lower and control blood pressure in hypertensive patients. Furthermore, associated with the increase in plasma-renin activity levels was a decrease in both diastolic and systolic blood pressure for PS433540 of up to 15 mmHg.

"While safety and tolerability of PS433540 across a broad range of doses up to 1,000 mg are the most important results of the MAD study, we are especially pleased to see, that even in healthy normotensive volunteers, signs of the compound's potential therapeutic activity are clearly discernable. Although preliminary, these results support the potential uti
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
2. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
3. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
4. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
5. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
6. Pharmacopeia Announces Third Quarter 2007 Financial Results
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2008)...dy finds the majority of acute lymphoblastic leuke...t at the time of diagnosis , , MEMPHIS, Ten...at St. Jude Children,s Research Hospital have iden...ells of children with acute lymphoblastic leukemia...thway to designing treatments for ALL relapse in c...
(Date:11/26/2008)...ed information density, automation and intelligent... ultrasound to an all new level , , CHICAGO... Healthcare ( www.siemens.com/healthcare ) hig...me Scanner (ABVS)(1), the world,s first multi-use...e 94th Scientific Assembly and Annual Meeting of t...
(Date:11/25/2008)... awareness can improve recovery , , Audio a... available on the Mayo Clinic News Blog. Please se... , ROCHESTER, Minn., Nov. 25 /PRNewswire-USNe... stroke patients don,t think they,re having a stro...ntil their condition worsens. The findings appear ...
(Date:11/25/2008)... reveal most respondents against expanding statin ..., LITTLE FALLS, N.J., Nov. 25 JU...y lower the cardiovascular risk of healthy patient...tatin use in older adults, according to a national... participants took part in the online poll conduct...
Breaking Medicine Technology:St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Strawberry fields ripe for the picking 1486 1Strawberry fields ripe for the picking 1486 2Making emergency artery repair safer 7749 1Jury Awards 245 25 Million Malpractice Verdict Against Fort Worth Doctor 7745 1Jury Awards 245 25 Million Malpractice Verdict Against Fort Worth Doctor 7745 2Blue Cross Foundation Invests in Community Health 7741 1Blue Cross Foundation Invests in Community Health 7741 2Blue Cross Foundation Invests in Community Health 7741 3Blue Cross Foundation Invests in Community Health 7741 4
...007 /PRNewswire-FirstCall/ --,Phosphagenics Limite... pre-clinical studies of its TPM-02 dermal drug de... leading topical,treatment for severe acne and an ...The proof of concept studies showed a three-fold i...nto the skin when formulated,with TPM-02 compared ...
...ewswire-USNewswire/ -- Childhood,cancers are fortu...ecial case, accounting for 7 percent of all childh...aths. It typically occurs as a,solid tumor in the ...developing in the network of the body,s sympatheti...ns call a heterogeneous disease;,its name includes...
Other Medicine Technology:Phosphagenics Announces Positive Proof of Concept Results from,Studies Utilizing Company's Dermal Drug Delivery Technology 2Neuroblastoma Expert Reviews Progress and Challenges in Fighting,Difficult Pediatric Cancer 2Neuroblastoma Expert Reviews Progress and Challenges in Fighting,Difficult Pediatric Cancer 3
(Date:12/1/2008)...wire-FirstCall/ -- The Ensign Group, Inc.,(Nasdaq... Rehabilitation Center in,Pocatello, Idaho has su... and,Medicaid Services, Special Focus program. ,...h/20071213/LATH168LOGO ) , A clinical team ...llo Care,& Rehabilitation Center, completed t...
(Date:12/1/2008)..., at Memorial Sloan-Kettering Cancer Center, New Y... expression of genes for therapeutic purposes, and... in mice. , Small, noncoding RNA molecules known... expression. In the study, the miRNA miR-181a was ...ne cells known as T cells at different stages of t...
(Date:12/1/2008)...irstCall/ -- ViroPharma Incorporated,(Nasdaq: V... supplemental,Biologics License Application (sBLA...for Cinryze(TM) C1 Inhibitor (human) as a treatmen...). , The sBLA is based on a re-analysis and...e treatment study of Cinryze and interim data from...
(Date:12/1/2008)...ty illnesses common, study shows , , MO...ders are common among young adults in the United S... , To reach this finding, U.S. researchers anal...9 to 25, who took part in the National Epidemiolog...The study found that 45.8 percent of the 2,188 col...
Breaking Medicine News(10 mins):Health News:The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program 2Health News:The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 4Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 5Health News:Few Young Adults Seek Treatment for Psych Disorders 2
...der unsanitary and freezing conditions in the coun...e and shell marine products.// The National Instit...bad conducted a study which reveals that many amon...n working in fish processing units are predominant...
...d that more devastating earthquakes are likely to ...50 years. // They will inflict far greater damage ... in Pakistan. Roger Bilham who has been working i... the past two months, said that a huge amount of e...
... Journal of Psychiatry that antidepressant drugs d...rather decrease the suicide risk. The article also...nt drugs should be closely monitored to find their... dosage can cause adverse conditions. The resea...
...nd news media to increase the awareness about chil...// to increase child survival. The Lancet reports ...achievable, Millennium Development Goal – 4 (MDG) ...en below the age of 5 and MDG-5 wants a reduction ...
Other Medicine News:Health News:Unregulated Fish Industry Harms Health Of Women 2Health News:More Severe Earthquakes May Hit Kashmir In Future 2
Clinician's Pocket Drug Reference 2005 includes key elements of commonly used medications that are essential information for both the student and practicing physician.
AHFS Patient Drug Information gives you a single source for providing important information and instructions for patients on dosing, precautions, possible side effects and interactions, and more.
Containing more than 600 full drug monographs, plus abbreviated monographs for combination drugs, orphan drugs and AIDS drugs in development, A to Z Drug Facts provides up-to-date information on more
Provides instant access to reliable information on herbs, minerals, vitamins, amino acids, probiotics, enzymes, over-the-counter hormones, and other dietary supplements commonly used by consumers.
Medicine Products: